Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksOxford Biomedica Share News (OXB)

Share Price Information for Oxford Biomedica (OXB)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 329.50
Bid: 328.00
Ask: 331.00
Change: -5.00 (-1.49%)
Spread: 3.00 (0.915%)
Open: 329.00
High: 332.50
Low: 329.00
Prev. Close: 334.50
OXB Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract

Tue, 05th Mar 2024 17:09

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

STV Group PLC - Glasgow-based broadcaster - Revenue grows 22% to GBP168.4 million in 2023 from GBP137.8 million a year prior. Total advertising revenue drops 12% to GBP97.3 million from GBP110.0 million. Adjusted pretax profit was GBP9.5 million for the year, down from GBP24.1 million in 2022. STV's dividend was flat for the year at 11.3p per share, after a final dividend of 7.4p. STV has secured GBP87 million in future revenue as at March, GBP30 million a head of the same time a year ago, and the company is encouraged by the "resilience" shown by the advertising market in the year so far. Chief Executive Officer Simon Pitts says: "Our overall financial performance was impacted by weak linear advertising and cost inflation, as expected and related to the challenging UK macro environment, although the start of 2024 has been more encouraging."

----------

Avacta Group PLC- Wetherby, England-based life sciences company specialising in oncology treatments - Set to issue 10.9 million new shares at a price of 50p each following its February retail offer. This remains subject to shareholder approval at the company's annual general meeting on March 18. The REX offer received total applications in excess of the GBP6.8 million limit. The company decided to limit the offer to existing Avacta retail shareholders, and expects a total of GBP5.4 million to be raised from the offer. The company says the proceeds will be used to support the continued clinical development of AVA6000, the company's signature treatment capable of targeting a chemotherapy to the tumour while sparing healthy tissue.

----------

Argo Blockchain PLC - London-based cryptocurrency miner - Enters into agreement for sale of Mirabel, Quebec data centre for a total consideration of USD6.1 million. The proceeds from the sale will be used to repay the facility's outstanding mortgage in full, and the remainder used to pay debts owned to Galaxy Digital Holdings Ltd, an asset manager and trade advisor specialising in digital assets. As of February 29, the Galaxy debt stands at USD14.0 million. The company is in the process of moving mining machines out of the Mirabel facility, and expects the transaction to close by the end of March.

----------

Harland & Wolff Group Holdings PLC - London-based fabrication company, which serves the maritime and offshore industries - Says it has been awarded preferred bidder status for the Falkland Islands Port Replacement Project by the Falkland Islands Government. H&W believes this contract could generate total revenues between GBP100 and GBP120 million over a two-year period, with works on the project expected to commence this year.

----------

Oxford BioMedica PLC - Oxfordshire, England-based gene and cell-therapy company - Updates annual guidance, expecting 2024 revenue of around GBP126 million to GBP134 million. Guidance for the 2023 full-year remains unchanged, with group revenue expected to be around GBP90 million. The group is expecting a loss before interest, tax, depreciation and amortisation for 2023, but is targeting break-even operating Ebitda by the end of 2024.

----------

By Hugh Cameron, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
1 Dec 2020 14:29

UK DIRECTOR DEALINGS SUMMARY: Oxford BioMedica Non-Exec And Wife Sell

UK DIRECTOR DEALINGS SUMMARY: Oxford BioMedica Non-Exec And Wife Sell

Read more
9 Nov 2020 10:01

Oxford BioMedica, PhoreMost Team For Next-Gen Cell Therapy Development

Oxford BioMedica, PhoreMost Team For Next-Gen Cell Therapy Development

Read more
9 Nov 2020 09:16

Oxford Biomedica strikes collaboration agreement with PhoreMost

(Sharecast News) - Gene and cell therapy group Oxford Biomedica has inked a discovery collaboration agreement with UK-based biopharmaceutical company PhoreMost.

Read more
4 Nov 2020 09:40

UK BROKER RATINGS SUMMARY: BofA Raises Lloyds; Liberum Likes Landsec

UK BROKER RATINGS SUMMARY: BofA Raises Lloyds; Liberum Likes Landsec

Read more
30 Oct 2020 08:47

Oxford Biomedica partner delays Parkinson's disease treatment trial

(Sharecast News) - Gene and cell therapy group Oxford Biomedica said on Friday that partner Axovant Gene Therapies had pushed out the start date for its trial into a Parkinson's disease treatment.

Read more
23 Oct 2020 15:15

UK DIRECTOR DEALINGS SUMMARY: Liontrust Chiefs Bank GBP1.6 Million

UK DIRECTOR DEALINGS SUMMARY: Liontrust Chiefs Bank GBP1.6 Million

Read more
6 Oct 2020 14:19

Oxford BioMedica Notes Positive Follow-Up Data From AXO-Lenti-PD

Oxford BioMedica Notes Positive Follow-Up Data From AXO-Lenti-PD

Read more
6 Oct 2020 09:44

Another Manufacturing Suite At Oxford Biomedica's Oxbox Gets Approval

Another Manufacturing Suite At Oxford Biomedica's Oxbox Gets Approval

Read more
6 Oct 2020 07:55

LONDON BRIEFING: BHP To Increase Stake In Gulf Of Mexico Development

LONDON BRIEFING: BHP To Increase Stake In Gulf Of Mexico Development

Read more
6 Oct 2020 07:43

LONDON MARKET PRE-OPEN: Watches Of Switzerland Ups Full-Year Guidance

LONDON MARKET PRE-OPEN: Watches Of Switzerland Ups Full-Year Guidance

Read more
6 Oct 2020 07:03

Oxford Biomedica new manufacturing suite approved

(Sharecast News) - Oxford Biomedica said it had received government approval for a fourth manufacturing suite within its Oxbox facility which will be used to develop a potential Covid-19 vaccine.

Read more
17 Sep 2020 10:43

Oxford Biomedica Burns Bright Amid AstraZeneca Vaccine Deal

Oxford Biomedica Burns Bright Amid AstraZeneca Vaccine Deal

Read more
17 Sep 2020 08:35

LONDON MARKET OPEN: Stocks Tumble In US Fed's Wake And Ahead Of BoE

LONDON MARKET OPEN: Stocks Tumble In US Fed's Wake And Ahead Of BoE

Read more
17 Sep 2020 07:52

LONDON MARKET PRE-OPEN: Next Raises Full-Year Profit Outlook

LONDON MARKET PRE-OPEN: Next Raises Full-Year Profit Outlook

Read more
17 Sep 2020 07:01

Oxford Biomedica sees swing to FY profit on Covid vaccine hopes

(Sharecast News) - Drugs maker Oxford Biomedica, which has partnered with pharma giant AstraZeneca to develop a Covid-19 vaccine, said it expected higher second half revenues to push it to a low-to-single digit full year profit.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.